Lincoln, Neb.– Virtual Incision Corporation, developer of the FDA-authorized MIRA Surgical System, has appointed veteran medtech executive Jim Alecxih as its new Chief Executive Officer. The move comes as the company prepares to accelerate the development and commercialization of its next-generation surgical platform, the M2 system.
Alecxih brings over three decades of experience in advancing surgical technologies, most notably during his time at Intuitive Surgical, where he played a key role in driving national adoption of the da Vinci Surgical System. He has also held executive leadership positions at multiple healthcare startups and previously served as CEO of AI healthcare software firm DH Medical.
“The opportunity to lead Virtual Incision at this pivotal time is an extraordinary honor,” said Alecxih. “The M2 platform has the potential to greatly expand access to robotic-assisted surgery, especially in rural and underserved healthcare environments. I look forward to helping scale this vision globally.”
Virtual Incision’s M2 system is a miniaturized, single-port surgical robot designed to reduce the cost and complexity typically associated with large, cart-based robotic platforms. The company plans a series of FDA submissions to bring the M2 to multiple specialties and broaden its reach across hospitals, ambulatory surgical centers (ASCs), and hospital outpatient departments (HOPDs).
Tyler Stowater, partner at Bluestem Capital and a board member of Virtual Incision, praised the appointment. “Jim’s deep industry knowledge and proven leadership make him the ideal person to guide Virtual Incision through this next phase of innovation and market expansion.”
Alecxih’s leadership is expected to support the company’s mission of making robotic-assisted surgery more accessible, flexible, and scalable for diverse clinical settings worldwide.
